Compile Data Set for Download or QSAR
Report error Found 27 Enz. Inhib. hit(s) with all data for entry = 2021
TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207629(US9265734, R01 | US9796664, Compound R01)
Affinity DataIC50: 300nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM19410(benzamide-type inhibitor, 3 | CHEMBL27759 | pyridi...)
Affinity DataIC50: 590nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: 700nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: 700nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM19410(benzamide-type inhibitor, 3 | CHEMBL27759 | pyridi...)
Affinity DataIC50: 720nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207632(US9265734, R03 | US9796664, Compound R03)
Affinity DataIC50: 800nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207634(US9265734, R05 | US9796664, Compound R05)
Affinity DataIC50: 1.40E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207636(US9265734, R07 | US9796664, Compound R07)
Affinity DataIC50: 1.60E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207635(US9265734, R06 | US9796664, Compound R06)
Affinity DataIC50: 1.80E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207629(US9265734, R01 | US9796664, Compound R01)
Affinity DataIC50: 1.98E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: 2.00E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: 2.00E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207631(US9265734, R02 | US9796664, Compound R02)
Affinity DataIC50: 2.30E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207629(US9265734, R01 | US9796664, Compound R01)
Affinity DataIC50: 2.40E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM19410(benzamide-type inhibitor, 3 | CHEMBL27759 | pyridi...)
Affinity DataIC50: 3.20E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207637(US9265734, R08 | BDBM207672 | US9796664, Compound ...)
Affinity DataIC50: 3.60E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207628(US9265734, RGFA8 | US9796664, Compound RGFA8)
Affinity DataIC50: 3.73E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207635(US9265734, R06 | US9796664, Compound R06)
Affinity DataIC50: 5.70E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207638(US9265734, R09 | US9796664, Compound R09 | BDBM207...)
Affinity DataIC50: 7.30E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207632(US9265734, R03 | US9796664, Compound R03)
Affinity DataIC50: 8.20E+3nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207633(US9265734, R04 | US9796664, Compound R04)
Affinity DataIC50: 1.40E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207636(US9265734, R07 | US9796664, Compound R07)
Affinity DataIC50: 1.80E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207631(US9265734, R02 | US9796664, Compound R02)
Affinity DataIC50: 1.80E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207637(US9265734, R08 | BDBM207672 | US9796664, Compound ...)
Affinity DataIC50: 2.40E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207634(US9265734, R05 | US9796664, Compound R05)
Affinity DataIC50: 3.00E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207633(US9265734, R04 | US9796664, Compound R04)
Affinity DataIC50: 3.00E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Biomarin Pharmaceutical

US Patent
LigandPNGBDBM207638(US9265734, R09 | US9796664, Compound R09 | BDBM207...)
Affinity DataIC50: 3.00E+4nMAssay Description:HDAC inhibition assays can be performed, e.g., in a cell, in a cell extract, or in a cell-free mixture. Exemplary HDAC inhibition assays are describe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent